Compare +50 FDA Q-Submission Providers

This page is a decision framework for teams preparing an FDA Q-Submission (including Pre-Sub meeting requests). It is built around real buyer intent patterns such as "FDA pre-submission meeting timeline", "pre-sub briefing package help", and "Q-submission consultant for SaMD". Instead of generic agency lists, this directory helps you compare capabilities against your exact risk profile: novel technology level, evidence maturity, and internal bandwidth.

What this directory covers

FDA Q-Submission support varies widely. Some providers are deep in strategic meeting design, others are stronger in writing/editing the package, and some mostly focus on project management. To make comparison practical, use a consistent scorecard across five dimensions: regulatory depth, meeting strategy quality, briefing package quality, cross-functional execution, and responsiveness during final FDA preparation week.

Provider comparison framework

Dimension	What good looks like	Warning signal
Regulatory strategy depth	Uses classification, predicate, and evidence logic tied to your exact intended use.	Generic recommendations without citations to guidance or regulation.
Briefing package quality	Clear problem statement, specific questions, concise risk/benefit framing.	Long package with no decision-oriented question design.
Meeting-readiness process	Dry-run, Q&A matrix, owner mapping, and response playbooks.	No rehearsal process and unclear presenter roles.
Execution model	Transparent workplan, weekly deliverables, and version control.	Unstructured emails and unclear accountability.
Budget transparency	Clear scope, assumptions, and change-control triggers.	Open-ended hourly model with no cap assumptions.

How to select the right type of support

If you have strong in-house RA but limited time, prioritize providers with high editorial throughput and fast turnaround. If your team is early-stage and unclear on pathway assumptions, prioritize strategic depth and pre-meeting coaching. If your device is software-heavy or cybersecurity-sensitive, prioritize teams that can tie design controls, software documentation, and clinical claims into consistent FDA-facing reasoning. A provider can be excellent generally but still weak for your exact decision point.

For most teams, the best process is hybrid. Use software for repeatable structure, evidence organization, and drafting consistency, then use specialized experts for high-leverage judgment calls. This avoids paying premium rates for low-value formatting work while still preserving senior review where it matters most.

Use these calculators before you shortlist providers

Run these calculators first so your provider outreach is based on quantified assumptions, not rough estimates:

What to request in every provider proposal

Ask for an explicit deliverable map: problem framing memo, question architecture, briefing package draft timeline, meeting simulation plan, and post-meeting action template. Require a sample versioning process and ask how they ensure consistency between intended use language, risk statements, and evidence claims. Many delays begin with small language inconsistencies that propagate across sections.

Also ask each provider to identify where they believe your biggest risk is before contract signature. High-quality firms can usually identify one to three likely failure points quickly. If they cannot articulate concrete risks, that usually means generic process knowledge rather than case-specific insight.

Evidence and citations

This page is aligned to FDA and CDRH references for Q-Submission planning, meeting process, and decision quality:

Next step

After you run the three calculators and define your assumptions, send a structured RFP to providers using your own quantified scope. That one change typically improves quote quality, shortens sales cycles, and makes cross-provider comparison objective.

Build Your Submission Workflow